Estrogen/HRT (Menopause)

Estrogen hormone replacement therapy (HRT) represents one of the most extensively studied interventions for menopausal symptoms and age-related health changes in postmenopausal women. Research indicates that estrogen therapy can effectively reduce hot flashes, night sweats, and other vasomotor symptoms that affect quality of life during menopause. Studies also suggest potential benefits for bone health, with evidence showing reduced fracture risk, particularly in the hip and spine. The cardiovascular effects of HRT have been subject to extensive research, with studies indicating that timing of initiation may be crucial, as therapy started closer to menopause onset may provide cardiovascular benefits.

The Women's Health Initiative study fundamentally changed the understanding of HRT by demonstrating both benefits and risks associated with combined estrogen-progestin therapy. Research indicates that estrogen-only therapy in women without a uterus may have a different risk-benefit profile compared to combined therapy. Current evidence suggests that transdermal estrogen may have advantages over oral forms regarding blood clot risk and metabolic effects. Studies also indicate that the lowest effective dose for the shortest duration necessary to achieve treatment goals is the preferred approach.

The choice of estrogen formulation, delivery method, and whether to include progestin depends on individual factors including the presence of a uterus, personal and family medical history, and symptom severity. Research suggests that bioidentical hormones may offer similar efficacy to traditional synthetic hormones, though long-term comparative studies are limited. Clinical trials continue to investigate optimal dosing strategies, novel delivery methods, and personalized approaches to hormone therapy based on genetic factors and individual risk profiles.